Change of 5.51% for Catabasis Pharmaceuticals Inc (NASDAQ:CATB)’s short interest was recorded. It was published in February by FINRA the 986,300 short interest on CATB. The down change of 5.51% from 1.04M shares was reported. With Average volume 311,500, CATB’s previous position will take 3 days to restore.

Ticker’s shares touched $6.16 during the last trading session after 3.30% change.Catabasis Pharmaceuticals, Inc. has volume of 66,261 shares. Since February 2, 2018 CATB has declined 65.90% and is downtrending. The stock underperformed the S&P500 by 65.90%.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States.The firm is valued at $43.76 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD).Last it reported negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

For more Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) news posted briefly go to: Businesswire.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy – Business Wire” posted on November 02, 2018, “Catabasis Pharmaceuticals, Inc. (CATB) CEO Jill Milne on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” on November 13, 2018, “Catabasis Pharmaceuticals (CATB) CEO Jill Milne on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” with a publish date: August 09, 2018, “Catabasis Crashes And Sarepta Stumbles In DMD – Seeking Alpha” and the last “Oppenheimer sees 1H19 risk for smid-cap biotech – Seeking Alpha” with publication date: December 27, 2018.